Stem Cell Therapy Orlando Testimonial | Stem Cell Treatments Florida – Video

Posted on by


Stem Cell Therapy Orlando Testimonial | Stem Cell Treatments Florida
One of our patients has had successful results with our new revolutionary stem cell treatment in Orlando at Eterna MD. Please learn more at http://www.eterna...

By: Eterna MD Regenerative Medicine

Read the original here:
Stem Cell Therapy Orlando Testimonial | Stem Cell Treatments Florida - Video

Docs seek stop to expensive, experimental stem cell therapy

Posted on by

By Philip C. Tubeza Philippine Daily Inquirer

MANILA, PhilippinesSaying that doctors were exacting exorbitant fees for what is still experimental medicine, the Philippine College of Physicians (PCP) launched Tuesday an online petition urging the Department of Health (DOH) to put a stop to experimental stem cell therapies in the country.

Human stem cell therapy for unproven indications is proliferating in the Philippines and posing serious safety issues to unknowing Filipinos The Philippine College of Physicians is alarmed by the false claims, misinformation and exorbitant fees for such stem cell treatments, read the petition on http://www.change.org.

The PCP urged the DOH to issue a cease and desist order to all doctors performing such therapies as the Philippine Health Insurance Corp. (PhilHealth) clarified that stem cell therapy was not covered by the governments universal healthcare program.

Cease and desist

We, the undersigned, call on the (DOH) to issue a cease and desist order to all doctors, clinics and hospitals that [offer] human stem cell therapy for unproven indications until scientific evidence to support claims of efficacy and safety are approved by the Food and Drug Administration, it said.

The PCP, the umbrella organization of Internal Medicine specialists in the country, said that transplanting human blood-forming stem cells to treat cancerous and noncancerous diseases of the blood was the most widely accepted clinical application of stem cell therapy.

The effectiveness and safety of human stem cell therapy has yet to be proven for heart, neurologic, skin, rheumatologic and gastrointestinal diseases, diabetes, hypertension, autism, cancer, aging and aesthetics, HIV/AIDS and other conditions, the group said.

Lack of evidence

Despite the lack of solid scientific evidence to support the [application] of human stem cell therapy for these conditions, reports of its use precisely for these conditions being received and exorbitant fees being paid by prominent personalities abound in media, the PCP said.

Originally posted here:
Docs seek stop to expensive, experimental stem cell therapy

Clinical Exercise Physiology – Open Day 2013 – University of South Australia – Video

Posted on by


Clinical Exercise Physiology - Open Day 2013 - University of South Australia
If you #39;re interested in the principles of exercise and physical activity, and can see yourself working to help people with chronic injuries and illnesses lea...

By: UniSouthAustralia

More here:
Clinical Exercise Physiology - Open Day 2013 - University of South Australia - Video

Rhodes College student conducts research at St. Jude

Posted on by

As a participant in the 2013 Undergraduate Research Fellowship Program, Rhodes student Tina Dao, of Memphis, is conducting research at St. Jude.

Memphian and Rhodes College rising junior Tina Dao is participating in the 2013 Undergraduate Research Fellowship (URF) Program presented by the American Society for Microbiology (ASM).

The fellowship program is aimed at highly competitive students who wish to pursue graduate studies in microbiology.

Students conduct full-time research with an ASM member and present research results at the ASM General Meeting the following year.

Dao is conducting research with Michael Johnson, Ph.D. and Jason Rosch, Ph.D. in the Infectious Diseases Department of St. Jude Childrens Research Hospital for a minimum of 10 weeks.

Her research project examines the role of the copper efflux pump and the mechanism of copper-mediated toxicity in Streptococcus pyogenes, which cause strep throat, pneumonia, bacteremia, scarlet fever, pharyngitis, and flesh eating diseases.

A graduate of Wooddale High School in Memphis, Dao is now a biochemistry and molecular biology major at Rhodes.

Additionally, she is a member of the Rhodes Chapter of Gamma Sigma Epsilon Chemistry Honor Society.

Dionne Chalmers is with the Office of Communications at Rhodes College.

Read the original here:
Rhodes College student conducts research at St. Jude

SkinPro Targets the Thriving OTC Diet Pill Market With the Release of Tepamine

Posted on by

MIAMI, Aug. 21, 2013 (GLOBE NEWSWIRE) -- SkinPro is well known for recent innovations in skin care technology such as the new and revolutionary use of a peptide that mimics the effects of paralyzing viper venom on wrinkles and a tremendously popular syringe dispensed eye serum that has quickly become the #1 Best Seller on Amazon.com, the world's largest online retailer. A new and potent weight loss and anti-aging pill called Tepamine, is no exception to the pattern of innovation that both industry observers and customers have come to expect from SkinPro. Dispensed in a soluble pill form, Tepamine is a potent hydrochloride based formula that is primarily comprised of a high concentration of Norcoclaurine HCL, Yohimbine HCL and Synephrine HCL.

Norcoclaurine HCL, also known as Higenamine, boosts the heart rate and induces Lipolysis, which is the process where fat is freed up and used for energy. Norcoclaurine has been used for hundreds of years in traditional medicine. Yohimbine HCL is an active chemical found in yohimbe tree bark. It raises metabolism and increases blood circulation by increasing noadrenaline. It also targets Alpha-1 receptors and signals them to stop holding onto fat. Alpha-1 receptors are most commonly located in areas where stubborn fat is difficult to lose such as the belly and hips. Synephrine HCL is an alkaloid extract of bitter orange peels. It is structurally similar to ephedrine and it also acts as an adrenergic (adrenaline-like) stimulant. Synephrine HCL has the ability to speed up your metabolism without making you feel jittery or nervous because it stimulates only beta-3 receptor and not the other receptor sites. Furthermore, Synephrine HCL has been shown to also suppress the appetite and boost energy.

SkinPro CEO Tim Schmidt states, "We spent over 3 years researching and perfecting this formula. Leveraging our dominance in skin care and anti-aging, we created what we know will ultimately be referred to as the strongest, most effective OTC weight loss product on the market. With obesity reaching epidemic proportions in this country and throughout most of the world, that consumers truly need. It has been carefully designed with our unique and proprietary three-pronged mechanism of weight loss to function as an appetite suppressant, fat blocker and metabolic driver. We hope that this will help consumers burn that extra fat, even in those places that they think are impossible to reach. Not wanting to stray too far from our core fundamentals, we have designed and integrated a world class and vital anti-aging blend that will help turn back the clock from the inside out. The early feedback we've received from our beta testers so far is nothing short of astounding."

Learn more about Tepamine by visiting the official website at http://www.Tepamine.com.

Read more:
SkinPro Targets the Thriving OTC Diet Pill Market With the Release of Tepamine

Target 2 forms of iron to control cystic fibrosis lung infection

Posted on by

Public release date: 20-Aug-2013 [ | E-mail | Share ]

Contact: Jim Sliwa jsliwa@asmusa.org 202-942-9297 American Society for Microbiology

The bacterium Pseudomonas aeruginosa needs iron to establish and maintain a biofilm in the lungs of cystic fibrosis patients, and therapies have been proposed to deprive the bacteria of this necessary element. However, these techniques may not work, according to a new study published in mBio, the online open-access journal of the American Society for Microbiology, because they only target one of the two types of iron that are available in the lung.

Current therapies focus on removing ferric iron [Fe(III)] but leave plenty of ferrous iron [Fe(II)] behind for the bacteria to use, according to the study. The concentration of Fe(II) present in the lungs of patients with cystic fibrosis correlates with disease severity, a sign that pathogens not only use ferrous iron - they thrive on it. These findings could have implications for treatment of P. aeruginosa in patients with cystic fibrosis.

"It is clear that the percentage of the total iron pool that is Fe(II) is substantial, particularly in severely ill patients," write the authors. Despite a wealth of data on the abundance of iron in the airways of patients with cystic fibrosis, this study is the first to make direct measurements of two different bioavailable forms of iron, Fe(III) and Fe(II).

An optimal concentration of bioavailable iron is needed to establish the formation of P. aeruginosa biofilms, thick accumulations of bacteria, polysaccharides, and cellular debris that can build up in the lungs of cystic fibrosis patients. It's also integral to stabilizing biofilms, so therapies have been proposed to perturb P. aeruginosa's uptake and acquisition of iron to fight biofilm development in the lung.

Because Fe(III) is commonly assumed to be the dominant physiologically-relevant form of iron, therapies focus on blocking Fe(III) acquisition. However, Fe(II) may also be present in the lung, reasoned the authors, a fact that could undermine iron-targeting therapies.

They tested sputum samples from a cross-section of 33 cystic fibrosis patients from the US and Belgium. Fe(II) was, indeed, abundant in the lungs of cystic fibrosis patients, and it comprised a considerable amount of the total iron in each sample, confirming the authors' suspicions. What's more, sicker patients had greater quantities of Fe(II), and while Fe(II) concentration was significantly correlated with disease the concentration of Fe(III) was not.

The authors also tested whether inhibiting the uptake of Fe(II) or Fe(III) - or both - would prevent biofilm formation. Using a high-throughput biofilm assay in the lab, they tested the ability of ferrozine, an Fe(II)-specific chelator, and conalbumin, a Fe(III)-specific chelator, to bind iron and prevent the buildup of a biofilm. They found that in a system where both Fe(II) and Fe(III) are present, as they are in the lungs of cystic fibrosis patients, it was most effective to apply both types of chelators: sequestering both forms of iron resulted in a 58% reduction in biofilm accumulation. This suggests that for treating patients, targeting both forms of iron might be more effective than targeting Fe(III) alone.

"Collectively, these studies underscore the importance of a dialectic between laboratory and environmental studies of pathogens such as P. aeruginosa," write the authors. Mechanistic studies of microorganisms in the laboratory can only go so far without real-world information about the chemical conditions under which they live in the human body. The integrated approach used in this study has provided a superior understanding of how iron availability might be manipulated to prevent biofilm formation and can inform the effective design and application of therapeutic strategies for treating P. aeruginosa biofilms.

Continue reading here:
Target 2 forms of iron to control cystic fibrosis lung infection

FDA hearing on stem cell therapy set on Friday, Aug. 23

Posted on by

By: Jet Villa, InterAksyon.com August 18, 2013 5:02 PM

REUTERS FILE PHOTO

InterAksyon.com The online news portal of TV5

MANILA, Philippines - The Food and Drug Administration (FDA) will conduct on Friday, August 23, a public hearing on the regulation of stem cell therapy in the country.

The FDA said the public hearing is scheduled from 3 p.m. to 5 p,m, at the Audio-Visual Room, 3rd floor, Annex Building, FDA office on Civil Drive in Alabang Muntinlupa.

The purpose of the hearing is to discuss the regulation of stem cell therapy, the stem cell products, and the health facilities that are offering the service in the court, it said.

The FDA also established an online reporting system to document adverse events linked to human cells, tissues, and cellular- and tissue-based products such stem cell therapies acquired in any facility.

The agency said those who experienced any untoward event or side effect or treatment failures after undergoing stem cell procedures can report through FDA website at http://www.fda.gov.ph under eReport and Adverse Drug Reaction, Report section.

E-mails may also be sent toreport@fda.gov.ph.

All consumers are assuredthat all information given will be treated with utmost confidentiality.Contact details are needed in case of a need for follow-up and validation.However, anonymous reports will still be accepted, the FDA added.

More:
FDA hearing on stem cell therapy set on Friday, Aug. 23

BioTime CEO Dr. Michael West to Give Keynote Address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine …

Posted on by

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West, PhD will give the keynote address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine conference on Monday, August 19, 2013, at 12:15 p.m. EDT in Cleveland, Ohio. Dr. West will discuss the potential use of embryonic mesenchymal progenitor cells, generated using BioTimes PureStemtechnology, in regenerative medicine and will contrast the properties of those cells with adult-derived mesenchymal stem cells. He will also discuss how those cells can be utilized in the search for genes potentially useful in induced tissue regeneration (iTR). The presentation will be available on BioTimes website at http://www.biotimeinc.com/scientific-presentations.

MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine, August 19-21, 2013, is being held at the Cleveland Marriott Downtown at Key Center and is presented by Case Western Reserve University and the National Center for Regenerative Medicine.

About BioTime, Inc

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTimes focus is on pluripotent stem cell technology based on human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTimes therapeutic and research products include a wide array of proprietary PureStem progenitors, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (a HyStem product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. In addition, BioTime has developed Hextend, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements.

BioTime is also developing stem cell and other products for research, therapeutic, and diagnostic use through its subsidiaries:

Additional information about BioTime can be found on the web at http://www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.

Read more from the original source:
BioTime CEO Dr. Michael West to Give Keynote Address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine ...